Literature DB >> 29285391

F18-fluorodeoxyglucose positron emission tomography/computed tomography for bone hemangiopericytoma.

Yiyan Liu1.   

Abstract

Bone hemangiopericytoma (HPC) is extremely rare, and its clinical manifestations and radiographic features are nonspecific. There are few case reports about application of F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in HPC. A total of four subjects with pathologically diagnosed bone HPC had FDG PET/CT for staging and/or restaging bone HPC. Medical records were retrospectively reviewed for radiological, pathological and follow-up information. All primary bone and metastatic lesions demonstrated high FDG avidity on PET/CT, which also revealed the adjacent soft tissue involvement and synchronous lesion. PET/CT correctly detected metastatic lesions in 1 patient. Furthermore, 3/4 patients with available laboratory data had hypocalcemia, but normal phosphorus levels when HPC existed as primary lesions or metastatic disease; however, normalization of calcium levels when they were disease-free. The results suggested that FDG PET/CT could be effectively used for staging, surveillance and detection of recurrent/metastatic disease in HPC. There may be an association between bone HPC and hypocalcemia.

Entities:  

Keywords:  F18-fluorodeoxyglucose positron emission tomography/computed tomography; bone hemangiopericytoma; hypocalcemia; paraneoplastic syndrome

Year:  2017        PMID: 29285391      PMCID: PMC5740833          DOI: 10.3892/mco.2017.1458

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  23 in total

1.  Malignant hemangiopericytoma of the bone.

Authors:  H R Dürr; A Nerlich; A Lienemann; P E Müller; H J Refior
Journal:  Langenbecks Arch Surg       Date:  2000-04       Impact factor: 3.445

2.  Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma.

Authors:  Carlos Fuentealba; Delia Pinto; Francisco Ballesteros; Daniel Pacheco; Oscar Boettiger; Néstor Soto; Wanda Fernandez; Fernando Gabler; Gilberto Gonzales; Antonio J Reginato
Journal:  J Clin Rheumatol       Date:  2003-12       Impact factor: 3.517

3.  Mechanisms of tumor-induced hypoglycemia with intraabdominal hemangiopericytoma.

Authors:  J Chung; R R Henry
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

4.  Hemangioma, hemangiopericytoma, and hemangioendothelioma (angiosarcoma) of bone.

Authors:  K K Unni; J C Ivins; J W Beabout; D C Dahlin
Journal:  Cancer       Date:  1971-06       Impact factor: 6.860

5.  A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone.

Authors:  Sofie L J Verbeke; Christopher D M Fletcher; Marco Alberghini; Søren Daugaard; Adrienne M Flanagan; Tim Parratt; Herman M Kroon; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

6.  F-18 FDG PET/CT findings of primary sinonasal hemangiopericytoma: rare location in a young adult patient.

Authors:  Mustafa Aras; Fuat Dede; Tunc Ones; Beste Melek Atasoy; Sabahat Inanir; Tanju Yusuf Erdil; Halil Turgut Turoglu
Journal:  Clin Nucl Med       Date:  2011-06       Impact factor: 7.794

7.  Primary vascular tumors of bone: a spectrum of entities?

Authors:  Sofie L J Verbeke; Judith V M G Bovée
Journal:  Int J Clin Exp Pathol       Date:  2011-07-25

Review 8.  Solitary fibrous tumour and haemangiopericytoma: evolution of a concept.

Authors:  C Gengler; L Guillou
Journal:  Histopathology       Date:  2006-01       Impact factor: 5.087

9.  Conventional hemangiopericytoma: modern analysis of outcome.

Authors:  N Joseph Espat; Jonathan J Lewis; Denis Leung; James M Woodruff; Christina R Antonescu; Jingu Shia; Murray F Brennan
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

10.  Diagnostic importance of contrast enhanced (18)F-fluorodeoxyglucose positron emission computed tomography in patients with tumor induced osteomalacia: Our experience.

Authors:  Avani S Jain; Simon Shelley; Indirani Muthukrishnan; Shilpa Kalal; Jaykanth Amalachandran; Sureshkumar Chandran
Journal:  Indian J Nucl Med       Date:  2016 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.